These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 10550197)

  • 1. Urokinase and the US Food and Drug Administration.
    Ouriel K
    J Vasc Surg; 1999 Nov; 30(5):957-8. PubMed ID: 10550197
    [No Abstract]   [Full Text] [Related]  

  • 2. The case of Abbokinase and the FDA: the events leading to the suspension of Abbokinase supplies in the United States.
    Hartnell GG; Gates J
    J Vasc Interv Radiol; 2000; 11(7):841-7. PubMed ID: 10928519
    [No Abstract]   [Full Text] [Related]  

  • 3. Manufacturing misdeeds cost Abbott record-breaking payment.
    Lewis C
    FDA Consum; 2000; 34(3):38-9. PubMed ID: 11521253
    [No Abstract]   [Full Text] [Related]  

  • 4. From the Food and Drug Administration.
    Nightingale SL
    JAMA; 1999 Mar; 281(9):786. PubMed ID: 10070983
    [No Abstract]   [Full Text] [Related]  

  • 5. Possible use of monoclonal antibodies to standardize the production and use of human urokinase.
    Harris WJ; Weston J; Gilmour J; Hart H
    Dev Biol Stand; 1984; 57():349-54. PubMed ID: 6543201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The contamination with coagulative substance in urokinase preparation (author's transl)].
    Shiba T; Igarashi M; Hirose K; Takeuchi S; Awazu S; Asada T
    Nihon Ketsueki Gakkai Zasshi; 1979 Jun; 42(3):537-40. PubMed ID: 495012
    [No Abstract]   [Full Text] [Related]  

  • 7. A collaborative study to establish a standard for high molecular weight urinary-type plasminogen activator (HMW/u-PA).
    Gaffney PJ; Heath AB
    Thromb Haemost; 1990 Nov; 64(3):398-401. PubMed ID: 2128969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 45 hospitals warehouse new drug.
    Mod Healthc; 1978 May; 8(5):28. PubMed ID: 147992
    [No Abstract]   [Full Text] [Related]  

  • 9. Off-label use of interventional medical devices.
    Smith JJ; Berlin L
    AJR Am J Roentgenol; 1999 Sep; 173(3):539-42. PubMed ID: 10470876
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of plasminogen activators.
    Robbins KC; Barlow GH; Nguyen G; Samama MM
    Semin Thromb Hemost; 1987 Apr; 13(2):131-8. PubMed ID: 3114881
    [No Abstract]   [Full Text] [Related]  

  • 11. Urokinase to return to market.
    Traynor K
    Am J Health Syst Pharm; 2002 Dec; 59(23):2278. PubMed ID: 12489364
    [No Abstract]   [Full Text] [Related]  

  • 12. Stability and sterility of recombinant tissue plasminogen activator at -30 degrees C.
    Wiernikowski JT; Crowther M; Clase CM; Ingram A; Andrew M; Chan AK
    Lancet; 2000 Jun; 355(9222):2221-2. PubMed ID: 10881901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report.
    Duffy MJ; O'Grady P; Devaney D; O'Siorain L; Fennelly JJ; Lijnen HJ
    Cancer; 1988 Aug; 62(3):531-3. PubMed ID: 3134120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperacute stroke therapy with tissue plasminogen activator.
    Alberts MJ
    Am J Cardiol; 1997 Aug; 80(4C):29D-34D; discussion 35D-39D. PubMed ID: 9284041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator.
    Booth NA; Anderson JA; Bennett B
    J Clin Pathol; 1984 Jul; 37(7):772-7. PubMed ID: 6235248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional thrombolytic infusion for peripheral arterial occlusion: is urokinase really the drug of choice?
    Weber JJ; Chong K
    Am J Health Syst Pharm; 1998 Nov; 55(22):2414-6. PubMed ID: 9825039
    [No Abstract]   [Full Text] [Related]  

  • 17. [Tissue-type plasminogen activator and pro-urokinase--new fibrinolytic agents in the treatment of myocardial infarction].
    Czyrski J
    Wiad Lek; 1989 Apr; 42(7):450-2. PubMed ID: 2516932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
    Gurewich V; Pannell R
    Thromb Haemost; 1987 Jun; 57(3):372-3. PubMed ID: 3116707
    [No Abstract]   [Full Text] [Related]  

  • 19. Human platelet activation by thrombolytic agents: effects of tissue-type plasminogen activator and urokinase on platelet surface P-selectin expression.
    Kawano K; Aoki I; Aoki N; Homori M; Maki A; Hioki Y; Hasumura Y; Terano A; Arai T; Mizuno H; Ishikawa K
    Am Heart J; 1998 Feb; 135(2 Pt 1):268-71. PubMed ID: 9489975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human synovial fibroblasts produce urokinase-type plasminogen activator.
    Medcalf RL; Hamilton JA
    Arthritis Rheum; 1986 Nov; 29(11):1397-401. PubMed ID: 3096341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.